Are Analysts Bullish about Sinclair Pharma plc (LON:SPH) after last week?

June 17, 2018 - By Clifton Ray

Investors sentiment decreased to 0.85 in Q1 2018. Its down 0.32, from 1.17 in 2017Q4. It fall, as 14 investors sold Sinclair Pharma plc shares while 38 reduced holdings. 16 funds opened positions while 28 raised stakes. 17.28 million shares or 2.47% more from 16.86 million shares in 2017Q4 were reported.
Community Bancorporation Na owns 10 shares for 0% of their portfolio. Clearbridge Investments Limited Company accumulated 723,827 shares or 0.02% of the stock. Tower Ltd Limited Liability Company (Trc) holds 14,023 shares. Federated Invsts Pa accumulated 0.01% or 188,963 shares. Bb&T Securities Ltd holds 11,009 shares. Brown Brothers Harriman And has invested 0% in Sinclair Pharma plc (LON:SPH). Delta Asset Llc Tn holds 0% or 168 shares in its portfolio. Goldman Sachs Grp Inc Inc owns 1.06M shares or 0.01% of their US portfolio. Moreover, Glenmede Trust Na has 0% invested in Sinclair Pharma plc (LON:SPH) for 1,056 shares. Jpmorgan Chase And reported 1.36 million shares stake. Janney Montgomery Scott Ltd Llc, a Pennsylvania-based fund reported 78,993 shares. Alphamark Ltd Liability Corporation accumulated 200 shares. Sumitomo Mitsui Holding Inc invested in 28,000 shares. Pennsylvania-based Peoples Services Corp has invested 0% in Sinclair Pharma plc (LON:SPH). Moreover, Benjamin F Edwards And has 0% invested in Sinclair Pharma plc (LON:SPH).

Since February 20, 2018, it had 0 buys, and 2 sales for $120,936 activity. Swift Jane had sold 1,000 shares worth $23,600 on Monday, March 5.

Sinclair Pharma plc (LON:SPH) Ratings Coverage

Among 3 analysts covering Sinclair IS Pharma PLC (LON:SPH), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Sinclair IS Pharma PLC had 12 analyst reports since January 15, 2018 according to SRatingsIntel. The stock of Sinclair Pharma plc (LON:SPH) earned “Buy” rating by Peel Hunt on Monday, April 30. The company was maintained on Wednesday, April 4 by Peel Hunt. The stock of Sinclair Pharma plc (LON:SPH) has “Hold” rating given on Thursday, February 22 by Numis Securities. The stock has “Hold” rating by Numis Securities on Monday, April 30. The rating was maintained by Peel Hunt with “Buy” on Thursday, January 18. The firm has “Buy” rating by Peel Hunt given on Monday, January 15. The stock of Sinclair Pharma plc (LON:SPH) has “Buy” rating given on Thursday, May 31 by Peel Hunt. RBC Capital Markets maintained the shares of SPH in report on Monday, April 30 with “Outperform” rating. The company was maintained on Wednesday, June 13 by Peel Hunt. The stock of Sinclair Pharma plc (LON:SPH) has “Buy” rating given on Thursday, February 22 by Peel Hunt. Below is a list of Sinclair Pharma plc (LON:SPH) latest ratings and price target changes.

13/06/2018 Broker: Peel Hunt Rating: Buy Old Target: GBX 42.00 Maintain
31/05/2018 Broker: Peel Hunt Rating: Buy Old Target: GBX 42.00 Maintain
30/04/2018 Broker: Numis Securities Rating: Hold Maintain
30/04/2018 Broker: RBC Capital Markets Rating: Outperform Old Target: GBX 53.00 New Target: GBX 43.00 Maintain
30/04/2018 Broker: Peel Hunt Rating: Buy New Target: GBX 42.00 Maintain
04/04/2018 Broker: Peel Hunt Rating: Buy Old Target: GBX 48.00 Maintain
26/03/2018 Broker: Peel Hunt Rating: Buy Old Target: GBX 48.00 New Target: GBX 48.00 Maintain
22/02/2018 Broker: Numis Securities Rating: Hold Old Target: GBX 21.00 New Target: GBX 21.00 Maintain
22/02/2018 Broker: Peel Hunt Rating: Buy Old Target: GBX 48.00 New Target: GBX 48.00 Maintain
18/01/2018 Broker: Peel Hunt Rating: Buy Old Target: GBX 68.00 New Target: GBX 48.00 Maintain

The stock increased 0.13% or GBX 0.02 during the last trading session, reaching GBX 19.75. About 15,189 shares traded. Sinclair Pharma plc (LON:SPH) has 0.00% since June 17, 2017 and is . It has underperformed by 12.57% the S&P500.

Sinclair Pharma plc, a specialty pharmaceutical company, engages in the manufacture, commercialization, and sale of dermatological products worldwide. The company has market cap of 99.49 million GBP. It provides Silhouette Soft, a resorbable poly-L-lactic acid/PLGA suture with bi-directional resorbable cones for skin repositioning and tightening; and Ellansé, which offers dermal fillers. It currently has negative earnings. The firm also provides Perfectha for wrinkle correction, facial contouring, and volume restoration; and Sculptra designed to stimulate collagen growth.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: